JP2010519224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519224A5 JP2010519224A5 JP2009550160A JP2009550160A JP2010519224A5 JP 2010519224 A5 JP2010519224 A5 JP 2010519224A5 JP 2009550160 A JP2009550160 A JP 2009550160A JP 2009550160 A JP2009550160 A JP 2009550160A JP 2010519224 A5 JP2010519224 A5 JP 2010519224A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cytarabine
- leukemia
- daunorubicin
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90177207P | 2007-02-16 | 2007-02-16 | |
| US60/901,772 | 2007-02-16 | ||
| US96519607P | 2007-08-17 | 2007-08-17 | |
| US60/965,196 | 2007-08-17 | ||
| PCT/US2008/054168 WO2008101214A2 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519224A JP2010519224A (ja) | 2010-06-03 |
| JP2010519224A5 true JP2010519224A5 (OSRAM) | 2011-04-07 |
| JP5314600B2 JP5314600B2 (ja) | 2013-10-16 |
Family
ID=39690832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550160A Active JP5314600B2 (ja) | 2007-02-16 | 2008-02-15 | 造血器癌および増殖性疾患の治療のための固定した薬物比 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100303895A1 (OSRAM) |
| EP (3) | EP3300601B1 (OSRAM) |
| JP (1) | JP5314600B2 (OSRAM) |
| KR (2) | KR20100014441A (OSRAM) |
| CN (1) | CN105998046A (OSRAM) |
| AU (1) | AU2008216083B2 (OSRAM) |
| CA (1) | CA2678332C (OSRAM) |
| CY (1) | CY1119631T1 (OSRAM) |
| DK (2) | DK2120568T3 (OSRAM) |
| ES (2) | ES2909903T3 (OSRAM) |
| FR (1) | FR22C1034I2 (OSRAM) |
| HR (1) | HRP20220428T3 (OSRAM) |
| HU (2) | HUE058334T2 (OSRAM) |
| LU (1) | LUC00271I2 (OSRAM) |
| NL (1) | NL301185I2 (OSRAM) |
| NO (2) | NO2120568T3 (OSRAM) |
| PL (2) | PL3300601T3 (OSRAM) |
| PT (2) | PT2120568T (OSRAM) |
| SI (1) | SI3300601T1 (OSRAM) |
| WO (1) | WO2008101214A2 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075937A1 (en) * | 2008-09-24 | 2010-03-25 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
| CA2852777C (en) | 2011-10-21 | 2020-10-27 | Celator Pharmaceuticals Inc. | Lyophilized liposomes |
| US20140154304A1 (en) * | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA3219061A1 (en) * | 2015-11-11 | 2017-05-18 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
| MX2021003527A (es) * | 2018-09-25 | 2021-05-27 | Celator Pharmaceuticals Inc | Tratamiento de baja intensidad de trastornos hematologicos. |
| CA3121902A1 (en) | 2018-12-04 | 2020-06-11 | Der-Yang Tien | Stereocomplexes for the delivery of anti-cancer agents |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11980636B2 (en) * | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2025088367A1 (en) * | 2023-10-27 | 2025-05-01 | Jodas Expoim Pvt. Ltd | Liposomal composition of idarubicin and cytarabine and process for preparation thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| BR0316002A (pt) * | 2002-11-06 | 2005-09-13 | Celgene Corp | Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit |
| WO2004043461A1 (en) * | 2002-11-06 | 2004-05-27 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| PT1744764E (pt) * | 2004-04-22 | 2012-08-30 | Celator Pharmaceuticals Inc | Formulações lipossómicas de agentes antraciclina e análogos de citidina |
| SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| US20090148506A1 (en) | 2005-12-22 | 2009-06-11 | Awa Dicko | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
-
2008
- 2008-02-15 SI SI200832194T patent/SI3300601T1/sl unknown
- 2008-02-15 JP JP2009550160A patent/JP5314600B2/ja active Active
- 2008-02-15 EP EP17200498.8A patent/EP3300601B1/en active Active
- 2008-02-15 US US12/526,930 patent/US20100303895A1/en not_active Abandoned
- 2008-02-15 WO PCT/US2008/054168 patent/WO2008101214A2/en not_active Ceased
- 2008-02-15 HU HUE17200498A patent/HUE058334T2/hu unknown
- 2008-02-15 US US12/032,583 patent/US8092828B2/en active Active
- 2008-02-15 PL PL17200498T patent/PL3300601T3/pl unknown
- 2008-02-15 EP EP22150734.6A patent/EP4046640A1/en active Pending
- 2008-02-15 HR HRP20220428TT patent/HRP20220428T3/hr unknown
- 2008-02-15 NO NO08730048A patent/NO2120568T3/no unknown
- 2008-02-15 ES ES17200498T patent/ES2909903T3/es active Active
- 2008-02-15 DK DK08730048.9T patent/DK2120568T3/en active
- 2008-02-15 CN CN201610324431.2A patent/CN105998046A/zh active Pending
- 2008-02-15 EP EP08730048.9A patent/EP2120568B1/en not_active Revoked
- 2008-02-15 PT PT87300489T patent/PT2120568T/pt unknown
- 2008-02-15 PL PL08730048T patent/PL2120568T3/pl unknown
- 2008-02-15 PT PT172004988T patent/PT3300601T/pt unknown
- 2008-02-15 AU AU2008216083A patent/AU2008216083B2/en active Active
- 2008-02-15 CA CA2678332A patent/CA2678332C/en active Active
- 2008-02-15 KR KR1020097019393A patent/KR20100014441A/ko not_active Ceased
- 2008-02-15 DK DK17200498.8T patent/DK3300601T3/da active
- 2008-02-15 KR KR20157007810A patent/KR20150038752A/ko not_active Ceased
- 2008-02-15 ES ES08730048.9T patent/ES2650167T3/es active Active
-
2017
- 2017-11-29 CY CY20171101251T patent/CY1119631T1/el unknown
-
2022
- 2022-06-29 LU LU00271C patent/LUC00271I2/en unknown
- 2022-06-30 NO NO2022027C patent/NO2022027I1/no unknown
- 2022-07-05 FR FR22C1034C patent/FR22C1034I2/fr active Active
- 2022-07-05 NL NL301185C patent/NL301185I2/nl unknown
- 2022-07-07 HU HUS2200032C patent/HUS2200032I1/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519224A5 (OSRAM) | ||
| Zhanel et al. | The glycylcyclines: a comparative review with the tetracyclines | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| AR031978A1 (es) | Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion | |
| JP2009536147A5 (OSRAM) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2009525343A5 (OSRAM) | ||
| JP2010540616A5 (OSRAM) | ||
| JP2009269923A5 (OSRAM) | ||
| EP1173178A4 (en) | COMPOSITION OF APOMORPHINE AND SILDENAFIL | |
| CN106421793A (zh) | 用于治疗中枢介导的恶心及呕吐的组合物及方法 | |
| NZ606383A (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| JP2013541583A5 (OSRAM) | ||
| JP2009543885A5 (OSRAM) | ||
| JP2006513184A5 (OSRAM) | ||
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2019511529A5 (OSRAM) | ||
| JP2008540364A5 (OSRAM) | ||
| JP2005508963A5 (OSRAM) | ||
| JP2008517991A5 (OSRAM) | ||
| JP2010538066A5 (OSRAM) | ||
| Kok et al. | Cisplatin and etoposide in oesophageal cancer: a phase II study | |
| HRP20090679T1 (hr) | Upotreba oksikodona za liječenje organske boli | |
| JP2006503095A5 (OSRAM) | ||
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении |